Alternative Investments - Gold, REITs, Crypto, Commodities, etc.

Tag: Real Estate Investing

Innovative Industrial Properties IIPR investment illustration featuring cannabis real estate, biotech facilities, a $1M insider buy and 14.7% yield.

🌿 Innovative Industrial Properties ($IIPR): $1M Insider Buy, 14.7% Yield & the Biotech Pivot 🌿🧪

Innovative Industrial Properties ($IIPR) is stirring up an extraordinary investment debate. Its executive chairman just invested $1 million in preferred shares, the common stock offers an indicated dividend yield near 14.7%, institutional ownership approaches 80%, and short interest exceeds 15%. Meanwhile, a $270 million life sciences investment could reshape this battered cannabis REIT. Is IIPR an overlooked income-and-recovery opportunity—or a dividend trap? We examine the evidence through the FunStock Method™. FunStock Index™: 7.65/10. 🌿🧪

Read entire article

Tags: AFFO, Alan Gold, Biotechnology, BlackRock, buy or sell IIPR, Cannabis REIT, Cannabis Stocks, CannabisREIT, Deep Value Stocks, Dividend Sustainability, Dividend Trap, featured-diversify, featured-insiders, featured-value, FUNanc1al, FunStock Index, FunStock Method, FunStockIndex, High Dividend Stocks, HighYield, hub-diversify, hub-insiders, hub-value, IIPR, IIPR Dividend, IIPR Dividend Yield, IIPR Preferred Stock, IIPR Stock, Income Investing, Innovative Industrial Properties, InnovativeIndustrialProperties, Insider Buying, Insider Trading, InsiderBuying, Institutional Ownership, IQHQ, Life Sciences Real Estate, Real Estate Investing, REIT Investing, REITs, risks buying IIPR, Short Interest, Short Squeeze, Value Investing, why buy IIPR
Illustration of a futuristic life science research campus under reconstruction, with cranes and glowing laboratory buildings, symbolizing Alexandria Real Estate’s turnaround in biotech real estate.

Alexandria Real Estate (ARE): The Life Science “Dr. Frankenstein” Pivot — Rebuilding the Lab from the Floor Up

Alexandria Real Estate (ARE) is the king of life science labs—and one of the most punished REITs of the last five years. After a brutal dividend cut, asset write-downs, and a 75% drawdown, the founder just bought $1.3M of stock and the company is buying back shares. Is this a broken experiment—or a classic cycle-bottom setup?

 

Read entire article

Tags: Alexandria Real Estate, ARE, Biotech, Biotech Real Estate, BiotechInvesting, BiotechTurnarounds, buy or sell ARE, Dividend Stocks, featured-diversify, featured-insiders, FUNanc1al, FUNanc1al Edge, Healthcare Real Estate, hub-diversify, hub-insiders, Income Investing, Insider Buying, Lab Space, Life Science REIT, Real Estate Investing, REIT, risks buying ARE, Stock Analysis, Turnaround Stocks, Value Investing, why buy ARE